HRP20191366T4 - Injekcijski pripravak - Google Patents
Injekcijski pripravak Download PDFInfo
- Publication number
- HRP20191366T4 HRP20191366T4 HRP20191366TT HRP20191366T HRP20191366T4 HR P20191366 T4 HRP20191366 T4 HR P20191366T4 HR P20191366T T HRP20191366T T HR P20191366TT HR P20191366 T HRP20191366 T HR P20191366T HR P20191366 T4 HRP20191366 T4 HR P20191366T4
- Authority
- HR
- Croatia
- Prior art keywords
- salt
- quinolin
- benzo
- butoxy
- preparation according
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims 39
- 150000003839 salts Chemical class 0.000 claims 43
- 238000002347 injection Methods 0.000 claims 18
- 239000007924 injection Substances 0.000 claims 18
- 239000000375 suspending agent Substances 0.000 claims 18
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims 17
- 229960004372 aripiprazole Drugs 0.000 claims 17
- 229940079593 drug Drugs 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 14
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 claims 13
- 239000007788 liquid Substances 0.000 claims 11
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 10
- 239000002202 Polyethylene glycol Substances 0.000 claims 10
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 10
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 10
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 10
- 229920001223 polyethylene glycol Polymers 0.000 claims 10
- 239000011164 primary particle Substances 0.000 claims 10
- 238000000034 method Methods 0.000 claims 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 8
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 3
- 229940071643 prefilled syringe Drugs 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 239000000084 colloidal system Substances 0.000 claims 2
- 238000013265 extended release Methods 0.000 claims 2
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000025307 bipolar depression Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000004683 dihydrates Chemical group 0.000 claims 1
- 239000002270 dispersing agent Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 239000011163 secondary particle Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261636938P | 2012-04-23 | 2012-04-23 | |
| US201361792089P | 2013-03-15 | 2013-03-15 | |
| EP13728542.5A EP2841054B2 (en) | 2012-04-23 | 2013-04-23 | Injectable preparation |
| PCT/JP2013/062683 WO2013162048A1 (en) | 2012-04-23 | 2013-04-23 | Injectable preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20191366T1 HRP20191366T1 (hr) | 2019-12-27 |
| HRP20191366T4 true HRP20191366T4 (hr) | 2022-08-19 |
Family
ID=48614096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191366TT HRP20191366T4 (hr) | 2012-04-23 | 2013-04-23 | Injekcijski pripravak |
Country Status (31)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR090775A1 (es) | 2012-04-23 | 2014-12-03 | Otsuka Pharma Co Ltd | Preparado inyectable |
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| TWI562991B (en) * | 2012-04-23 | 2016-12-21 | Otsuka Pharma Co Ltd | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same |
| CN105461703B (zh) * | 2014-12-29 | 2019-05-17 | 深圳市泛谷药业股份有限公司 | 一种brexpiprazole的制备方法 |
| JP6513461B2 (ja) * | 2015-04-14 | 2019-05-15 | 帝國製薬株式会社 | ブレクスピプラゾールの経皮吸収製剤 |
| CN104829603A (zh) * | 2015-05-19 | 2015-08-12 | 杭州新博思生物医药有限公司 | A晶型依匹唑派盐酸盐及其制备方法 |
| WO2017134038A1 (en) * | 2016-02-01 | 2017-08-10 | Hexal Ag | Anhydrate-free polymorphically pure micronized crystalline brexpiprazole dihydrate for use in intramuscular injectable sustained release formulations |
| US11235976B2 (en) * | 2017-01-26 | 2022-02-01 | Sichuan Yingrui Pharmaceutical Technology Company | Nanocarbon-iron composite system as well as composition, preparation method and use thereof |
| US10987303B2 (en) | 2018-05-02 | 2021-04-27 | LifeMax Laboratories, Inc. | Extended release suspension formulation of lurasidone |
| WO2020089942A2 (en) * | 2018-11-02 | 2020-05-07 | Amaterasu Lifesciences Llp | A liquid injectable composition |
| WO2021199076A1 (en) * | 2020-03-30 | 2021-10-07 | Cipla Limited | Injectable aripiprazole formulation |
| PL4125903T3 (pl) * | 2020-04-01 | 2025-02-03 | Otsuka Pharmaceutical Co., Ltd. | Sposoby rozpoczynania podawania leczenia arypiprazolem |
| US20230372317A1 (en) * | 2020-10-27 | 2023-11-23 | Pts Consulting, Llc | A liquid injectable composition of donepezil |
| US11229644B1 (en) * | 2020-12-31 | 2022-01-25 | Lake O'hara Llc | Methods of treating psychiatric disorders in obese patients with brexpiprazole |
| US11910794B2 (en) | 2021-03-08 | 2024-02-27 | Monsanto Technology Llc | Solutions and methods for long-term pollen storage |
| WO2023067664A1 (ja) * | 2021-10-18 | 2023-04-27 | 大塚製薬株式会社 | ベンゾチオフェン化合物の新規結晶形及びその製造方法 |
| JP7760615B2 (ja) * | 2022-06-16 | 2025-10-27 | ウィズダム・ファーマスーティカル・カンパニー・リミテッド | 薬物組成物及びブレクスピプラゾール口腔内溶解フィルム |
| CN115969785A (zh) * | 2022-12-30 | 2023-04-18 | 辰欣药业股份有限公司 | 一种阿立哌唑注射剂及其制备方法 |
| CA3197997A1 (en) * | 2023-03-17 | 2025-01-23 | Otsuka Pharmaceutical Co., Ltd. | METHODS FOR DISPERSING INJECTABLE PREPARATIONS OF ARIPIPRAZOLE |
| TW202448470A (zh) | 2023-04-26 | 2024-12-16 | 日商大塚製藥股份有限公司 | 用於以阿立哌唑治療思覺失調症或第一型雙極性疾患之劑量起始 |
| WO2025051281A1 (zh) * | 2023-09-08 | 2025-03-13 | 广州玻思韬控释药业有限公司 | 注射用依匹哌唑凝胶 |
| WO2025183016A1 (ja) * | 2024-02-26 | 2025-09-04 | 大塚製薬株式会社 | Ｑｕａｂｏｄｅｐｉｓｔａｔ含有組成物 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB864100A (en) * | 1957-04-09 | 1961-03-29 | Pfizer & Co C | Therapeutic pencillin compositions and the preparation thereof |
| JPS5913714A (ja) | 1982-07-13 | 1984-01-24 | Taito Pfizer Kk | 外用消炎鎮痛剤 |
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| US5192802A (en) | 1991-09-25 | 1993-03-09 | Mcneil-Ppc, Inc. | Bioadhesive pharmaceutical carrier |
| JP4012994B2 (ja) | 1996-05-08 | 2007-11-28 | 大塚製薬株式会社 | 抗不安薬 |
| US20020076437A1 (en) | 2000-04-12 | 2002-06-20 | Sanjeev Kothari | Flashmelt oral dosage formulation |
| US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
| AR032641A1 (es) | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
| MY129350A (en) | 2001-04-25 | 2007-03-30 | Bristol Myers Squibb Co | Aripiprazole oral solution |
| PE20030445A1 (es) * | 2001-09-25 | 2003-07-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| JP2003171264A (ja) * | 2001-12-07 | 2003-06-17 | Taiyo Yakuhin Kogyo Kk | マイクロカプセル及びその製造方法 |
| JP2003238393A (ja) | 2002-02-15 | 2003-08-27 | Otsuka Pharmaceut Co Ltd | 施錠性が改善された錠剤及びその製造方法 |
| HRP20050149B1 (hr) * | 2002-08-20 | 2014-09-12 | Otsuka Pharmaceutical Co., Ltd. | Formulacija aripiprazol kompleksa i postupak |
| CN1989968B (zh) | 2002-12-27 | 2011-05-11 | 大塚制药株式会社 | 用于治疗情绪障碍的喹诺酮衍生物和5-羟色胺再摄取抑制剂 |
| DE60302139T3 (de) | 2003-01-09 | 2011-02-24 | Otsuka Pharmaceutical Co., Ltd. | Verfahren zur herstellung von aripiprazole |
| WO2004064752A2 (en) | 2003-01-22 | 2004-08-05 | Alkermes Controlled Therapeutics, Inc. | Method of preparing sustained release microparticles |
| CA2523484A1 (en) * | 2003-05-02 | 2004-11-11 | Rimon Therapeutics Ltd. | Thermally reversible implant |
| MXPA05012538A (es) | 2003-05-23 | 2006-02-22 | Otsuka Pharma Co Ltd | Derivados de carbostirilo y estabilizantes del estado de animo para trastornos del mismo. |
| US6987111B2 (en) | 2003-08-06 | 2006-01-17 | Alkermes Controlled Therapeutics, Ii | Aripiprazole, olanzapine and haloperidol pamoate salts |
| US20050032811A1 (en) | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| TWI371274B (en) | 2003-10-23 | 2012-09-01 | Bristol Myers Squibb Co | Process for making sterile aripiprazole of desired mean particle size |
| JP4836797B2 (ja) | 2003-10-23 | 2011-12-14 | 大塚製薬株式会社 | 放出制御性無菌注射アリピプラゾール製剤および方法 |
| CN1893931B (zh) | 2003-10-27 | 2011-07-20 | 陶氏康宁公司 | 局部用制剂及将活性剂传递给基底的方法 |
| EP2633853A1 (en) | 2004-01-12 | 2013-09-04 | The Trustees of The University of Pennsylvania | Long-term delivery formulations and methods of use thereof |
| JP2006219380A (ja) * | 2005-02-08 | 2006-08-24 | Minofuaagen Seiyaku:Kk | グリチルリチン皮下注射製剤 |
| TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| CA2622758A1 (en) | 2005-09-15 | 2007-03-29 | Elan Pharma International, Limited | Nanoparticulate aripiprazole formulations |
| ES2437581T3 (es) | 2005-11-17 | 2014-01-13 | Zogenix, Inc. | Suministro de formulaciones viscosas por inyección sin aguja |
| JP4373983B2 (ja) | 2006-01-27 | 2009-11-25 | 三菱電機インフォメーションシステムズ株式会社 | 流通経路管理装置及び流通経路管理プログラム |
| GB0618879D0 (en) * | 2006-09-26 | 2006-11-01 | Zysis Ltd | Pharmaceutical compositions |
| KR20090087441A (ko) * | 2006-10-05 | 2009-08-17 | 파나세아 바이오테크 리미티드 | 새로운 형태의 주입형 데포 조성물 및 이를 위한 조제방법 |
| JP4540700B2 (ja) | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
| US20100151459A1 (en) | 2007-01-26 | 2010-06-17 | Jun Soo Kwon | Marker for detecting the proposed efficacy of treatment |
| EP2170300B1 (en) | 2007-06-25 | 2014-12-31 | Otsuka Pharmaceutical Co., Ltd. | Microspheres having core/shell structure |
| MX2010001311A (es) | 2007-07-31 | 2010-04-21 | Otsuka Pharma Co Ltd | Metodo para producir una suspensi?n de aripiprazol y formulacion liofilizada. |
| WO2009026473A2 (en) * | 2007-08-21 | 2009-02-26 | Hollis-Eden Pharmaceuticals, Inc. | Stabilized therapeutic compositions and formulations |
| JP2011136906A (ja) * | 2008-04-18 | 2011-07-14 | Otsuka Pharmaceut Co Ltd | 複素環化合物 |
| JP2009286740A (ja) | 2008-05-30 | 2009-12-10 | Otsuka Pharmaceut Co Ltd | アリピプラゾールを含有する逆耐性抑制剤 |
| TR200809200A1 (tr) | 2008-12-01 | 2009-12-21 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Meloksikam içeren farmasötik formülasyonlar |
| US20100316725A1 (en) | 2009-05-27 | 2010-12-16 | Elan Pharma International Ltd. | Reduction of flake-like aggregation in nanoparticulate active agent compositions |
| SG178938A1 (en) | 2009-09-11 | 2012-04-27 | Otsuka Pharma Co Ltd | Therapeutic agent for chronic pain |
| MX344235B (es) * | 2010-08-24 | 2016-12-07 | Otsuka Pharmaceutical Co Ltd * | Suspension y composicion en torta que contiene un derivado de carbostirilo y aceite de silicona y/o un derivado de aceite de silicona. |
| JP5893616B2 (ja) * | 2010-10-18 | 2016-03-23 | 大日本住友製薬株式会社 | 注射用徐放性製剤 |
| AR083884A1 (es) | 2010-11-16 | 2013-03-27 | Otsuka Pharma Co Ltd | Jeringa prellenable de doble camara y relleno de aripiprazol en la jeringa |
| JP2012121850A (ja) | 2010-12-09 | 2012-06-28 | Otsuka Pharmaceut Co Ltd | アリピプラゾールの経口速溶性組成物 |
| DK2667856T3 (da) | 2011-01-24 | 2021-08-30 | Otsuka Pharma Co Ltd | Medicinsk indretning indeholdende en tørstofsammensætning omfattende aripiprazol som en aktiv ingrediens, og en tørstofsammensætning omfattende aripiprazol som en aktiv ingrediens |
| TWI636784B (zh) | 2011-04-05 | 2018-10-01 | 大塚製藥股份有限公司 | 含7-〔4-(4-苯並〔b〕噻吩-4-基-哌-1-基)丁氧基〕-1H-喹啉-2-酮之醫藥組成物與套組，以及彼之用途 |
| JP2012232958A (ja) † | 2011-05-09 | 2012-11-29 | Otsuka Pharmaceut Co Ltd | 注射製剤 |
| JO3410B1 (ar) | 2011-06-07 | 2019-10-20 | Otsuka Pharma Co Ltd | تركيبة أريبيبرازول مجفف بالتبريد |
| CN102846543B (zh) * | 2011-06-27 | 2014-11-19 | 上海中西制药有限公司 | 一种阿立哌唑药物制剂及其制备方法 |
| TW201309651A (zh) | 2011-06-29 | 2013-03-01 | Otsuka Pharma Co Ltd | 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法 |
| CN103717587B (zh) | 2011-07-28 | 2016-02-10 | 大塚制药株式会社 | 制造苯并[b]噻吩化合物的方法 |
| JO3227B1 (ar) | 2011-09-08 | 2018-03-08 | Otsuka Pharma Co Ltd | مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان |
| JO3753B1 (ar) | 2011-10-14 | 2021-01-31 | Otsuka Pharma Co Ltd | قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه |
| JO3190B1 (ar) | 2011-10-19 | 2018-03-08 | Otsuka Pharma Co Ltd | محلول للتناول عن طريق الفم |
| TW201332572A (zh) | 2011-12-28 | 2013-08-16 | Otsuka Pharma Co Ltd | 具有經取代的β－環糊精之藥物製劑 |
| JP2013139441A (ja) | 2011-12-28 | 2013-07-18 | Otsuka Pharmaceut Co Ltd | マイクロスフェア |
| TW201343201A (zh) | 2012-03-06 | 2013-11-01 | Otsuka Pharma Co Ltd | 持續釋放型口服固體製劑 |
| AR090775A1 (es) | 2012-04-23 | 2014-12-03 | Otsuka Pharma Co Ltd | Preparado inyectable |
| JOP20200109A1 (ar) * | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| TWI562991B (en) | 2012-04-23 | 2016-12-21 | Otsuka Pharma Co Ltd | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same |
-
2012
- 2012-04-23 JO JOP/2020/0109A patent/JOP20200109A1/ar unknown
-
2013
- 2013-04-22 AR ARP130101321A patent/AR090776A1/es not_active Application Discontinuation
- 2013-04-23 HR HRP20191366TT patent/HRP20191366T4/hr unknown
- 2013-04-23 TW TW109130917A patent/TW202126303A/zh unknown
- 2013-04-23 SG SG11201406451SA patent/SG11201406451SA/en unknown
- 2013-04-23 SI SI201331550T patent/SI2841054T2/sl unknown
- 2013-04-23 TW TW112130297A patent/TW202425992A/zh unknown
- 2013-04-23 EA EA201491685A patent/EA026619B1/ru not_active IP Right Cessation
- 2013-04-23 MX MX2014012811A patent/MX359241B/es active IP Right Grant
- 2013-04-23 KR KR1020247015029A patent/KR20240068788A/ko not_active Ceased
- 2013-04-23 DK DK13728542.5T patent/DK2841054T4/da active
- 2013-04-23 BR BR112014026307-8A patent/BR112014026307B1/pt active IP Right Grant
- 2013-04-23 KR KR1020147032714A patent/KR102138852B1/ko active Active
- 2013-04-23 MY MYPI2023004225A patent/MY210484A/en unknown
- 2013-04-23 EP EP19169193.0A patent/EP3539534A1/en active Pending
- 2013-04-23 MX MX2018010879A patent/MX387891B/es unknown
- 2013-04-23 PL PL13728542.5T patent/PL2841054T5/pl unknown
- 2013-04-23 CA CA2869889A patent/CA2869889C/en active Active
- 2013-04-23 TW TW111116460A patent/TW202313036A/zh unknown
- 2013-04-23 JO JOP/2013/0116A patent/JO3632B1/ar active
- 2013-04-23 EP EP13728542.5A patent/EP2841054B2/en active Active
- 2013-04-23 JP JP2015506529A patent/JP6234996B2/ja active Active
- 2013-04-23 LT LTEP13728542.5T patent/LT2841054T/lt unknown
- 2013-04-23 CN CN201810143716.5A patent/CN108186556B/zh active Active
- 2013-04-23 TW TW107109282A patent/TWI713826B/zh active
- 2013-04-23 WO PCT/JP2013/062683 patent/WO2013162048A1/en not_active Ceased
- 2013-04-23 AU AU2013253374A patent/AU2013253374B2/en active Active
- 2013-04-23 MY MYPI2014002932A patent/MY178573A/en unknown
- 2013-04-23 CA CA3120297A patent/CA3120297A1/en active Pending
- 2013-04-23 TW TW113144877A patent/TW202535396A/zh unknown
- 2013-04-23 UA UAA201411954A patent/UA115444C2/uk unknown
- 2013-04-23 PT PT13728542T patent/PT2841054T/pt unknown
- 2013-04-23 MY MYPI2018001894A patent/MY198007A/en unknown
- 2013-04-23 KR KR1020217029406A patent/KR20210116702A/ko not_active Ceased
- 2013-04-23 CN CN202210169142.5A patent/CN114344259B/zh active Active
- 2013-04-23 KR KR1020207015451A patent/KR102498075B1/ko active Active
- 2013-04-23 NZ NZ630335A patent/NZ630335A/en unknown
- 2013-04-23 CN CN201380021440.9A patent/CN104470499B/zh active Active
- 2013-04-23 SG SG10201608753UA patent/SG10201608753UA/en unknown
- 2013-04-23 ES ES13728542T patent/ES2743706T5/es active Active
- 2013-04-23 TW TW102114410A patent/TWI637752B/zh active
- 2013-04-23 US US14/396,380 patent/US20150093442A1/en not_active Abandoned
- 2013-04-23 HU HUE13728542A patent/HUE045979T2/hu unknown
- 2013-04-23 SG SG10201913425VA patent/SG10201913425VA/en unknown
-
2014
- 2014-10-09 ZA ZA2014/07335A patent/ZA201407335B/en unknown
- 2014-10-23 IL IL235299A patent/IL235299B/en active IP Right Grant
- 2014-10-23 PH PH12014502379A patent/PH12014502379B1/en unknown
- 2014-11-21 CO CO14256422A patent/CO7151500A2/es unknown
-
2017
- 2017-09-11 US US15/701,202 patent/US20180055941A1/en not_active Abandoned
- 2017-09-14 AU AU2017228608A patent/AU2017228608C1/en active Active
- 2017-10-25 JP JP2017206658A patent/JP6470378B2/ja active Active
-
2018
- 2018-10-10 US US16/156,958 patent/US10517951B2/en active Active
-
2019
- 2019-01-07 AU AU2019200060A patent/AU2019200060A1/en not_active Abandoned
- 2019-01-16 JP JP2019005031A patent/JP2019070028A/ja active Pending
- 2019-03-07 PH PH12019500498A patent/PH12019500498A1/en unknown
- 2019-07-17 US US16/514,973 patent/US20190336607A1/en not_active Abandoned
- 2019-08-28 CY CY20191100912T patent/CY1122252T1/el unknown
-
2020
- 2020-02-07 US US16/785,268 patent/US20200179517A1/en not_active Abandoned
- 2020-06-24 AU AU2020204200A patent/AU2020204200B2/en active Active
- 2020-10-14 JP JP2020172902A patent/JP2021008512A/ja active Pending
- 2020-12-01 US US17/108,939 patent/US11097007B2/en active Active
-
2021
- 2021-08-04 US US17/444,469 patent/US11638757B2/en active Active
-
2022
- 2022-01-14 JP JP2022004098A patent/JP7293412B2/ja active Active
- 2022-09-27 AU AU2022241491A patent/AU2022241491B2/en active Active
- 2022-12-30 US US18/148,860 patent/US12016927B2/en active Active
-
2023
- 2023-06-06 JP JP2023092924A patent/JP7612758B2/ja active Active
-
2024
- 2024-05-13 US US18/662,049 patent/US20250121065A1/en active Pending
- 2024-12-24 JP JP2024226861A patent/JP2025041805A/ja active Pending
-
2025
- 2025-01-13 AU AU2025200229A patent/AU2025200229A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191366T4 (hr) | Injekcijski pripravak | |
| JP2015514751A5 (cg-RX-API-DMAC7.html) | ||
| JP2018048179A5 (cg-RX-API-DMAC7.html) | ||
| PH12019550088A1 (en) | Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery | |
| PH12015502290A1 (en) | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | |
| JP2014129360A5 (cg-RX-API-DMAC7.html) | ||
| NZ737862A (en) | High-concentration monoclonal antibody formulations | |
| MY161022A (en) | Dexmedetomidine premix formulation | |
| HRP20210980T1 (hr) | Stabilna bez konzervansa midrijatska i protuupalna otopina za injekciju | |
| JP2017525671A5 (cg-RX-API-DMAC7.html) | ||
| HRP20190841T4 (hr) | Injektabilna formulacija | |
| JP6094388B2 (ja) | ペメトレキセドを含む注射用組成物 | |
| JP2014518232A5 (cg-RX-API-DMAC7.html) | ||
| RU2015100905A (ru) | Сухой порошок для ингаляционного препарата, включающий сальметерола ксинафоат, флутиказона пропионат и тиотропия бромид, а также способ его изготовления | |
| RU2014148544A (ru) | Составы на основе полиинозиновой-полицитидиловой кислоты (poly(i:с)) для лечения инфекций верхних дыхательных путей | |
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| CN101862293B (zh) | 盐酸多西环素的油混悬液及其制备方法和应用 | |
| CL2016001148A1 (es) | Sistema multiparticulado para la administración oral de drogas, que comprende partículas de microgel que contienen un ingrediente farmacéutico activo, donde las partículas de microgel están dispersas en una composición líquida no acuosa proceso para prepararlo cápsulas que lo comprenden. | |
| CN106924172A (zh) | 一种石杉碱甲溶致液晶制剂及其制备方法 | |
| HRP20140215T1 (hr) | Kombinacija koja sadrži paklitaksel za lijeäśenje raka jajnika | |
| RU2017129375A (ru) | Интестинальный гель на основе леводопы и карбидопы и способы его применения | |
| BR102013032405A2 (pt) | Composição farmacêutica na forma de uma suspensão oral compreendendo uma fração de flavonoide e uma goma de xantano | |
| CN103536529A (zh) | 含头孢噻呋长效注射剂及制备方法 | |
| AR126033A2 (es) | Preparación inyectable, y jeringa prellenada que contiene la preparación inyectable | |
| HRP20211308T1 (hr) | Veterinarski postupak za izazivanje emeze |